PMID- 8024837
OWN - NLM
STAT- MEDLINE
DCOM- 19940805
LR  - 20091119
IS  - 0006-8969 (Print)
IS  - 0006-8969 (Linking)
VI  - 46
IP  - 4
DP  - 1994 Apr
TI  - [Significance of serum myosin light chain-1 level in neuroleptic malignant 
      syndrome].
PG  - 373-8
AB  - In Parkinson disease, the interruption of medication often results in neuroleptic 
      malignant syndrome, which is caused by acute inhibition of the dopaminergic 
      system. It is a serious question in the management of Parkinson disease, whether 
      episode of pyrexia is derived from neuroleptic malignant syndrome or other 
      origins. In this syndrome, muscle damage enhances serum titers of myogenic 
      enzymes and proteins. Myosin light chain-1 (MLC-1), which is a small fragment of 
      myosin, has been reported to show long lasting elevation compared with CK in 
      neuromuscular diseases and cardiac infarction. Then, we evaluated the clinical 
      significance of serum MLC-1 in six patients with neuroleptic malignant syndrome, 
      i.e., four cases of Parkinson disease, one multiple system atrophy and one 
      schizophrenia with acute administration of haloperidol. Muscle breakdown was 
      observed by the elevation of serum MLC-1 titer, which sustained several days 
      after normalization of serum CK titer. In two cases of Parkinson disease, high 
      level of serum MLC-1 was observed in spite of normal body temperature, which 
      suggested pre-clinical stage of neuroleptic malignant syndrome. Thus, we 
      concluded that the estimation of serum MLC-1 is useful in those patients with 
      high risk of neuroleptic malignant syndrome.
FAU - Konagaya, M
AU  - Konagaya M
AD  - Department of Neurology, Suzuka National Hospital, Mie, Japan.
FAU - Iida, M
AU  - Iida M
FAU - Konagaya, Y
AU  - Konagaya Y
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - No To Shinkei
JT  - No to shinkei = Brain and nerve
JID - 0413550
RN  - 0 (Myosin Light Chains)
RN  - 0 (myosin light chain I)
RN  - EC 2.7.3.2 (Creatine Kinase)
RN  - EC 3.6.4.1 (Myosins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Creatine Kinase/metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Myosin Light Chains
MH  - Myosins/*blood
MH  - Neuroleptic Malignant Syndrome/*blood
MH  - Parkinson Disease/blood
EDAT- 1994/04/01 00:00
MHDA- 1994/04/01 00:01
CRDT- 1994/04/01 00:00
PHST- 1994/04/01 00:00 [pubmed]
PHST- 1994/04/01 00:01 [medline]
PHST- 1994/04/01 00:00 [entrez]
PST - ppublish
SO  - No To Shinkei. 1994 Apr;46(4):373-8.